Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

From neuroprogression to neuroprotection: implications for clinical care.

Berk M, Conus P, Kapczinski F, Andreazza AC, Yücel M, Wood SJ, Pantelis C, Malhi GS, Dodd S, Bechdolf A, Amminger GP, Hickie IB, McGorry PD.

Med J Aust. 2010 Aug 16;193(4 Suppl):S36-40.

PMID:
20712560
2.

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.

Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS.

Neurosci Biobehav Rev. 2011 Jan;35(3):804-17. doi: 10.1016/j.neubiorev.2010.10.001. Epub 2010 Oct 8. Review.

PMID:
20934453
3.

Evidence and implications for early intervention in bipolar disorder.

Berk M, Hallam K, Malhi GS, Henry L, Hasty M, Macneil C, Yucel M, Pantelis C, Murphy B, Vieta E, Dodd S, McGorry PD.

J Ment Health. 2010 Apr;19(2):113-26. doi: 10.3109/09638230903469111. Review.

PMID:
20433320
4.

Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?

Lagace DC, Eisch AJ.

Psychiatr Clin North Am. 2005 Jun;28(2):399-414. Review.

PMID:
15826739
5.

Neuroprogression: pathways to progressive brain changes in bipolar disorder.

Berk M.

Int J Neuropsychopharmacol. 2009 May;12(4):441-5. doi: 10.1017/S1461145708009498. Epub 2008 Oct 16. No abstract available.

PMID:
18922203
6.

Early intervention in bipolar disorders: opportunities and pitfalls.

Berk M, Hallam K, Lucas N, Hasty M, McNeil CA, Conus P, Kader L, McGorry PD.

Med J Aust. 2007 Oct 1;187(7 Suppl):S11-4. Review.

PMID:
17908017
8.

Putative neuroprotective agents in neuropsychiatric disorders.

Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:135-45. doi: 10.1016/j.pnpbp.2012.11.007. Epub 2012 Nov 23. Review.

PMID:
23178231
9.

Mediators of allostasis and systemic toxicity in bipolar disorder.

Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F.

Physiol Behav. 2012 Apr 12;106(1):46-50. doi: 10.1016/j.physbeh.2011.10.029. Epub 2011 Nov 3. Review.

PMID:
22079584
10.

Valproate and neuroprotective effects for bipolar disorder.

Atmaca M.

Int Rev Psychiatry. 2009;21(4):410-3. doi: 10.1080/09540260902962206. Review.

PMID:
20374154
11.

Cognitive impairment in bipolar disorder: an overview.

Manove E, Levy B.

Postgrad Med. 2010 Jul;122(4):7-16. doi: 10.3810/pgm.2010.07.2170. Review.

PMID:
20675966
12.

Staging and neuroprogression in bipolar disorder: a systematic review of the literature.

Gama CS, Kunz M, Magalhães PV, Kapczinski F.

Rev Bras Psiquiatr. 2013 Mar;35(1):70-4. Review.

13.

Magnetic resonance findings in bipolar disorder.

Brambilla P, Glahn DC, Balestrieri M, Soares JC.

Psychiatr Clin North Am. 2005 Jun;28(2):443-67. Review.

PMID:
15826742
14.

Identifying and treating cognitive impairment in bipolar disorder.

Goldberg JF, Chengappa KN.

Bipolar Disord. 2009 Jun;11 Suppl 2:123-37. doi: 10.1111/j.1399-5618.2009.00716.x. Review.

PMID:
19538691
15.

Hypothalamic-pituitary-adrenal axis and bipolar disorder.

Daban C, Vieta E, Mackin P, Young AH.

Psychiatr Clin North Am. 2005 Jun;28(2):469-80. Review.

PMID:
15826743
16.

Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report.

Frey BN, Andreazza AC, Kunz M, Gomes FA, Quevedo J, Salvador M, Gonçalves CA, Kapczinski F.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):283-5. Epub 2006 Jul 20.

PMID:
16859818
17.

Cognition in bipolar disorder.

Osuji IJ, Cullum CM.

Psychiatr Clin North Am. 2005 Jun;28(2):427-41. Review.

PMID:
15826741
18.

Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.

Quiroz JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK.

Mol Psychiatry. 2004 Aug;9(8):756-76. Review.

PMID:
15136795
19.

Bipolar disorder: balancing mood states early in course of illness effects long-term prognosis.

Agren H, Backlund L.

Physiol Behav. 2007 Sep 10;92(1-2):199-202. Epub 2007 May 23.

PMID:
17631368
20.

Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder.

Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, Magalhães PV, Kapczinski F.

Expert Rev Neurother. 2013 Jul;13(7):827-42. doi: 10.1586/14737175.2013.811981. Review.

PMID:
23898853

Supplemental Content

Support Center